immunotherapy – Page 2

Dynamic Gut Microbiome Changes Enhance Immunotherapy Outcomes in Advanced Liver Cancer

By MedXY 09/21/2026

This longitudinal study reveals that gut microbiome remodeling during immune checkpoint inhibitor therapy in advanced liver cancer patients predicts clinical benefit, improving biomarker accuracy and survival stratification.

news Oncology Otorhinolaryngology

Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial

By MedXY 09/21/2026

PDS0101 combined with pembrolizumab demonstrated encouraging efficacy and safety in immune checkpoint inhibitor-naive HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, supporting further first-line evaluation.

news Oncology Otorhinolaryngology

Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival Outcomes

By MedXY 09/21/2026

A meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup's treatment.

Hematology-Oncology news Oncology

Distinct Roles of PD-L1 and PD-L2 in Primary Mediastinal Large B-Cell Lymphoma: Implications for Immune Therapeutics

By MedXY 09/20/2026

This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.

news OB/GYN & Women's Health Oncology

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial

By MedXY 09/14/2026

Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.

$Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia$

Hematology-Oncology news Pediatrics

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

By MedXY 09/06/2026

A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.

Clinical Updates Hematology-Oncology news

Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma

By MedXY 09/03/2026

Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.

Hematology-Oncology news Oncology

Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication

By MedXY 08/25/2026

This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.

Hematology-Oncology news

Engineering High-Avidity Cathepsin-G-Specific CAR T Cells: A Promising Therapeutic Strategy for Acute Myeloid Leukemia

By MedXY 08/23/2026

This article reviews the development of high-avidity cathepsin-G-specific CAR T cells engineered with enhanced functional features to selectively target acute myeloid leukemia without hematopoietic toxicity, highlighting their preclinical efficacy, mechanistic insights, and clinical potential.

Gastroenterology news Oncology

Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCC

By MedXY 08/22/2026

Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.

Gastroenterology news Oncology

Metabolic Checkpoint Role of PCK1 Deficiency in Promoting MASH-HCC via 12-HETE-Induced CD8+ T Cell Dysfunction

By MedXY 08/22/2026

PCK1 deficiency in hepatocytes drives metabolic reprogramming that fosters MASH-HCC progression by inducing CD8+ T cell dysfunction through 12-HETE-p38 signaling, highlighting a metabolic immunotherapy target to enhance anti-PD-1 efficacy.

Diabetes & Endocrinology news

Durability of β-Cell Function After Cessation of Baricitinib Immunotherapy in New-Onset Type 1 Diabetes

By MedXY 08/22/2026

Baricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.

Hematology-Oncology news Rheumatology

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis

By MedXY 08/16/2026

A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffective DMARDs.

news Oncology Otorhinolaryngology

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY 08/11/2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Hematology-Oncology news Oncology

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

By MedXY 08/10/2026

The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcomes for a challenging disease.

Hematology-Oncology news Oncology

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy

By MedXY 08/05/2026

Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.

news Oncology

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

By MedXY 07/16/2026

This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and durability.

Allergy & Immunology Diabetes & Endocrinology news

Distinct Immune Subtypes in Type 1 Diabetes: Implications for Disease Progression and Personalized Immunotherapy

By MedXY 07/14/2026

Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.

news Oncology Respiratory

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

By MedXY 07/14/2026

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, underscoring the need for cautious patient selection.

$CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives$

Clinical Updates news

CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives

By MedXY 07/13/2026

This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.